Xiaoyan Lv

Jan 9, 2025 | virologyj.biomedcentral.com | Pengpeng Li |Xiaoyan Lv |Hui Shen |Jiamin Fang |Mingrui Wei |Xiaoyan Liu | +1 more

ReferencesHidalgo A, Chilvers ER, Summers C, et al. The Neutrophil Life Cycle[J]. Trends Immunol. 2019;40(7):584–97. https://doi.org/10.1016/j.it.2019.04.013. Article  CAS  PubMed  Google Scholar  Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords[J]. Cell Mol Immunol. 2020;17(5):433–50. https://doi.org/10.1038/s41423-020-0412-0. Article  CAS  PubMed  PubMed Central  Google Scholar  Wormser GPK, L H. J.

Jan 17, 2024 | onlinelibrary.wiley.com | Min Wang |Xiaoyan Lv |Ying Wang |Yao Li

1 INTRODUCTION The incidence and mortality rate of malignant tumors remain high. Progressive malignancies can also seriously result in significant family and socio-economic burdens.1 There are usually asymptomatic manifestations in the early stages of malignant tumor development, and most patients are diagnosed in the middle or late stages, resulting in treatment difficulties.